Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21656880 | 0.95 | SLC6A3 (0.47) | SLC6A3SLC6A4LMNAALOX5APFEN1 | |
| SCHEMBL21628828 | 0.95 | SLC6A3 (0.47) | SLC6A3SLC6A4LMNAALOX5APFEN1 | |
| SCHEMBL21656920 | 0.89 | SLC6A3 (0.37) | SLC6A3LMNAMAOB | |
| SCHEMBL21657049 | 0.89 | SLC6A3 (0.40) | SLC6A3SLC6A4 | |
| SCHEMBL21628600 | 0.89 | SLC6A3 (0.38) | SLC6A3SLC6A4FEN1KDM1A | |
| SCHEMBL21656944 | 0.88 | HDAC6 (0.39) | SLC6A3SLC6A4KDM1A | |
| SCHEMBL21628657 | 0.88 | SLC6A3 (0.38) | SLC6A3SLC6A4FEN1 | |
| SCHEMBL21656788 | 0.87 | SLC6A3 (0.38) | SLC6A3SLC6A4KDM1A | |
| SCHEMBL21628578 | 0.84 | ALOX5AP (0.40) | SLC6A3LMNAALOX5APFEN1 | |
| SCHEMBL21656650 | 0.83 | SLC6A3 (0.42) | SLC6A3SLC6A4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406814-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2023-12-21 | — | — | US | disclosed |
| US-20230150923-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2021-04-15 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150923-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | SLC6A3 3970/4885SLC6A4 3395/4885LMNA 3327/4885 |
| US-11591289-B2 | Aromatic compounds | AHR, TYR, MUSK | SLC6A3 4040/4885SLC6A4 3517/4885LMNA 3083/4885 |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | SLC6A3 3970/4885SLC6A4 3395/4885LMNA 3327/4885 |
| US-20230406814-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | SLC6A3 3970/4885SLC6A4 3395/4885LMNA 3327/4885 |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | SLC6A3 3970/4885SLC6A4 3395/4885LMNA 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.